logo
Doctored by Charles Piller review – the scandal that derailed Alzheimer's research

Doctored by Charles Piller review – the scandal that derailed Alzheimer's research

The Guardian20-02-2025

Living to old age is quite literally the best thing that any of us could hope for, given the alternative. It's a cruel irony, then, that many of us who make it that far will begin to lose our sense of who we are due to dementia. If you're 65, you've got about a one in 20 chance of developing the most common form, Alzheimer's disease, in the next decade. At 75, it's about one in seven, while those fortunate enough to reach 85 face a one in three chance.
Given the toll this illness takes on sufferers and those around them, hundreds of millions of families around the world are desperate for a medical breakthrough – and for years, headlines have suggested that it might be imminent. Scientists had identified the cause of Alzheimer's, they promised, and potential cures were already being tested.
The subtitle of Doctored – Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimer's – serves as a spoiler as to how that story ends, at least for the moment. The fraud uncovered by a rag-tag group of researchers into academic integrity and extensively documented here by Charles Piller, an investigative journalist for the magazine Science, feels like the kind of scandal that should have had wall-to-wall coverage. And yet, outside scientific circles, it remains relatively low-profile.
The story is complicated, but a summary might go like this: for decades, something called the amyloid hypothesis has dominated research into Alzheimer's, determining how billions of dollars of public and private funding into new drugs was spent. The brains of people who had died with it showed clumps of sticky protein – called amyloid plaques – between neurons. It seemed logical that these might be responsible for the disease's symptoms. And while this became the main line of inquiry, it never quite delivered on its early promise. Many people with amyloid plaques didn't have signs of Alzheimer's, for example. Something seemed to be missing.
And then came what seemed like decisive proof: a 2006 paper from the University of Minnesota, which went on to become one of the most cited in the field, showed that a sub-type of amyloid led to memory impairment. It wasn't until 2022 that scientific sleuths suggested that key images on which the research relied might have been Photoshopped to better fit the hypothesis. At first, the scientists fought back against the claims, but the 2006 paper has now been retracted, as have others based around the same findings. As the book explains, investigations continue and several key figures involved deny any knowledge of wrongdoing.
The implication is that years of work and billions of dollars spent on Alzheimer's research may have been carried out on the basis of fraudulent evidence. The scale of the harm caused and damage done is likely to be incalculable.
Piller handles the difficult material patiently and meticulously, as you would expect of an experienced specialist reporter. As the book continues, it becomes an ever more uncomfortable read: the tale starts with the alleged fakery of images by one, or a handful, of scientists. By the end, we're left wondering if any research can really be trusted.
Doctored is clearly the result of brilliant and dogged journalism, but at times all of this work is easier to admire than it is to read. Piller tries to humanise his narrative with pen portraits of key figures, but his habit of doing several of these in a row – and formulaically telling us everyone's place of birth and what their parents and grandparents did – gets repetitive and frustrating.
Sign up to Bookmarks
Discover new books and learn more about your favourite authors with our expert reviews, interviews and news stories. Literary delights delivered direct to you
after newsletter promotion
That's a pity, as the scandal at the book's heart is one that more people should know about. The scientists behind the fraud may have set back the quest to find treatments for Alzheimer's by many years. For those making decisions on the future of scientific and medical research, this book should be compulsory reading.
Doctored: Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimer's by Charles Piller is published by Icon (£20). To support the Guardian and Observer, order your copy at guardianbookshop.com. Delivery charges may apply.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Scientists see amazing star explosion like never before
Scientists see amazing star explosion like never before

BBC News

timean hour ago

  • BBC News

Scientists see amazing star explosion like never before

Astronomers have discovered some of the largest explosions ever recorded in the in the journal Science Advances, experts say the blasts give out ten times as much energy in one year that our Sun will put out during its entire very advanced telescopes, scientists were able to see this new rare cosmic explosions which they have called 'extreme nuclear transients'. (ENTs).The explosions happen due to massive stars getting ripped apart by black holes. How do these huge explosions happen and how big are they? Extreme nuclear transients (ENTs) explosions occur when a supermassive black hole eats a huge star. The massive star is torn to pieces as it goes too close to the black hole. When this happens a huge amount of energy is released. One of these ENTs, which astronomers have named Gaia18cdj, released over 25 times more energy than the most powerful supernova ever discovered. The amount of energy it released is the same as 100 suns release in their entire lifetime! The project to discover what these explosion actually are has been years in the making. ENTs are rare and hard to find, but it is hoped that new upcoming equipment will help more of them be findings not only set a new record for cosmic explosions, but also open up exciting possibilities for future discoveries in the vast universe.

Alzheimer's research suffers 'devastating blow' after new drug rejected by NHS
Alzheimer's research suffers 'devastating blow' after new drug rejected by NHS

STV News

timean hour ago

  • STV News

Alzheimer's research suffers 'devastating blow' after new drug rejected by NHS

A woman who has Alzheimer's disease has said the progression of research has suffered a 'devastating blow' after a new drug was rejected for use by NHS Scotland. Donanemab delays the onset of dementia and works by targeting a cause of the disease, rather than just treating its symptoms. But the Scottish Medicines Consortium says there isn't enough evidence to prove how well it works. Recently retired Rynagh has lived an enviable life, growing up in Ireland, moving to the US, and attending New York University. Coming to Scotland, she expected to live out the rest of her life in peaceful retirement. Instead, she found out she had dementia. She's now thrown into finding a cure for Alzheimer's – and says the rejection of this drug is a massive blow. 'What would it take to approve a drug for dementia?', she said. 'Because it seems to be a lost in space for people. There aren't annual check-ups or anything like there are with other diseases. So there's no record of decline, which is unusual when you think about how progress is made with other diseases over time. 'Think about polio, leprosy, and cancer. They were known many years ago, but we don't talk about them because of the needs and the cost. 'And I understand that cost is a factor, but the burden on society, even in comparison to those other diseases, is tremendous. Absolutely. And only tremendous. It's not just the individual, it's the community, it's the family. 'It's the cost to the next generation for what they lose out by having to provide that care and not being able to support their own families, immediate families, in the way that they will.' Donanemab works when antibodies are given by infusion into a vein in the arm – they then bind with amyloids in the brain, a protein that builds up in Alzheimer's patients, and leads to cognitive decline. Those antibodies trigger immune cells, which clear the amyloid – and slow down the alzheimer's process. The Scottish Medicines Consortium rejected donanemab for use on the NHS as it said there wasn't 'enough evidence of how well it works.' Meanwhile manufacturer Lilly claims the decision 'does not consider … the clinical efficacy and cost-effectiveness' of the drug. It's left campaigners worried about the future of dementia research. Henry Simmons, chief executive of Alzheimer Scotland, said: 'The process that all drugs go through at present at the both the NHS in Scotland and England is a reasonable process however, we don't think it is a reasonable way to tackle the issues we face in terms of the size and scale of dementia, and what we are calling for is a rethink on that.' There's hope the SMC will reconsider the drug, but in the meantime, Rynagh hopes people living with dementia don't give up – and that awareness of the illness continues to grow. 'Well, when it comes down to it, it is the public', she added. 'And if the public doesn't have the awareness, they won't push. 'You know, like 66% is that about two thirds of people with dementia are women. Women typically are the caregivers, but then they need the care and it becomes this cycle and it is increasing instead of decreasing. 'And also with the population pyramid is kind of changing as well. We know that that the elderly population is getting bigger and that's it's a disaster that you should be able to see. 'It's not that you're seeing one seventh of the iceberg. We're now coming to the point where it's so far above the water, it should be that you can go around us and go through it and disperse it, but are not even talking about it at the level that we need to be talking about it.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country

'I donated my mum's body to Alzheimer's research instead she was blown to pieces'
'I donated my mum's body to Alzheimer's research instead she was blown to pieces'

Daily Record

time10 hours ago

  • Daily Record

'I donated my mum's body to Alzheimer's research instead she was blown to pieces'

Her son said 'she was strapped in a chair, and a detonation took place underneath her' One Arizona man thought he was donating his mother's body to science after her harrowing descent in Alzheimer's - only to discover he had been sent her cremated arm before the rest of her body was strapped to a chair and blown up. Jim Stauffer cared for his mother Doris throughout her illness before she died at 74 in 2013. He decided to donate her brain to science hoping to contribute to a cure for Alzheimer's disease. The family contacted Biological Resource Center, a local company that brokered the donation of human bodies for research. Within the hour, BRC dispatched a driver to collect Doris. ‌ Jim signed a form authorizing medical research on his mother's body. Ten days later, Jim received his mother's cremated remains - but it turns out her ashes were made up of a singular arm sawn off from her body. The rest of her corpse had met a violent fate. ‌ Doris' brain never was used for Alzheimer's research. Instead, her body became part of an Army experiment to measure damage caused by roadside bombs, reports the Irish Star. Internal BRC and military records show that at least 20 other bodies were also used in the blast experiments without permission of the donors or their relatives, a violation of U.S. Army policy. Jim had also ticked a box specifically banning any kind of experiments on Doris. BRC sold donated bodies like Stauffer's for $5,893 each. Jim said: "She was strapped in a chair, and a detonation took place underneath her to get an idea of what the human body goes through when a vehicle is hit by an IED. There was wording on this paperwork about performing tests that may involve explosions, and we said, 'No'." Army officials involved in the project said they never received the consent forms that donors or their families had signed. Rather, the officials said they relied on assurances from BRC that families had agreed to let the bodies be used in such experiments. ‌ BRC, which sold more than 20,000 parts from some 5,000 human bodies over a decade, is no longer in business. Its former owner, Stephen Gore, pleaded guilty to fraud in 2022. In a statement to Reuters, Gore said that he always tried to honor the wishes of donors and sent consent forms when researchers requested them. Jim said of Gore "He didn't care about the families, he didn't care about the people." Jim learned of the fate of his mother's body from a Reuters reporter and "curled his lip in anger and clutched his wife Lisa's arm. "We did right," Lisa reassured him. "They just did not honor our wishes." No federal law regulates body brokers like BRC, and no U.S. government agency monitors what happens to cadavers pledged for use in medical education and research. ‌ "It is not illegal to sell a whole body or the parts of a body for research or education," said University of Iowa law professor Sheldon F. Kurtz, who helped modify the Uniform Anatomical Gift Act, which has been adopted by 46 states. Although the act was updated in 2006, Kurtz said, "the issue of whole bodies or body parts for research or education never came up during our discussions." Since then, the body trade has become big business. Only one state, New York, keeps detailed records on the industry. According to the most recent data available, companies that did business in New York shipped at least 100,000 body parts across the country from 2011 to 2014. Reuters obtained the data, which have never been made public, from the state's health department. "I feel foolish," said Jim. "I'm not a trusting person, but, you have no idea this is going on." Military officials said they took BRC's word that permission had been given. Records show at least 20 more bodies were blown up without consent.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store